SRB
Steve R. Bailey Portfolio
Invests via Frazier Life Sciences Management LP | Managed by James W. Brush, M.D.
Invests via Frazier Life Sciences Management LP
Managed by James W. Brush, M.D.
Automatically Tracked
Steve R. Bailey Profile
Steve R. Bailey has carved a significant niche within the financial services sector, establishing himself as a seasoned investor-operator with a robust background in corporate finance and venture capital. His diverse experience spans various industries, including technology and healthcare, where he has played key roles in scaling innovative startups into market leaders. Known for his strategic acumen and hands-on approach to growth, he effectively bridges the gap between entrepreneurial ambition and operational execution. His leadership not only reflects an understanding of dynamic market demands but also positions him as an influential figure capable of navigating complex investment landscapes.
Steve R. Bailey has carved a significant niche within the financial services sector, establishing himself as a seasoned investor-operator with a robust background in corporate finance and venture capital. His diverse experience spans various industries, including technology and healthcare, where he has played key roles in scaling innovative startups into market leaders. Known for his strategic acumen and hands-on approach to growth, he effectively bridges the gap between entrepreneurial ambition and operational execution. His leadership not only reflects an understanding of dynamic market demands but also positions him as an influential figure capable of navigating complex investment landscapes.
Investment Philosophy & Strategy
Analyzing emerging market trends reveals significant investment opportunities in innovative sectors. Steve R. Bailey leverages his extensive operational expertise to identify and support companies that exhibit strong growth potential and scalable business models. His approach often combines hands-on mentorship with strategic capital deployment, emphasizing long-term value creation over short-term gains. Through meticulous evaluation of entrepreneurial ventures, he focuses on fostering resilience and competitive advantage among startups within the technology and healthcare industries. This blend of financial insight and operational rigor positions him uniquely to not only drive successful investments but also contribute positively to the broader economic landscape.
Analyzing emerging market trends reveals significant investment opportunities in innovative sectors. Steve R. Bailey leverages his extensive operational expertise to identify and support companies that exhibit strong growth potential and scalable business models. His approach often combines hands-on mentorship with strategic capital deployment, emphasizing long-term value creation over short-term gains. Through meticulous evaluation of entrepreneurial ventures, he focuses on fostering resilience and competitive advantage among startups within the technology and healthcare industries. This blend of financial insight and operational rigor positions him uniquely to not only drive successful investments but also contribute positively to the broader economic landscape.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
452.53%
Gain -5.73%
Monthly
3.64%
Yearly
53.64%
Drawdown
44.08%
$4.45B
Equity
Holdings
$4.45B
Investment
$2.24B
$2.87B
Profit -$84.82M
Realized
$656.88M
Unrealized
$2.21B
Dividends
$0
Goals
Avg. 90.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-5.73%
Profit
-$84.82M
Win %
82%
This Week
Compared To Last Week
Gain
-1.82%
Profit
-$82.45M
Win %
82%
This Month
Compared to last month
Gain
-0.71%
Profit
-$31.77M
Win %
82%
This Year
Compared to last year
Gain
4.06%
Profit
$173.57M
Win %
83%
VALN Valneva SE
+26.2%
+$3.39M 
ACHV Achieve Life Sciences Inc.
+4.69%
+$2.59M 
PHAT Phathom Pharmaceuticals Inc.
+4.36%
+$4.99M 
PBLS Parabilis Medicines, Inc.
+3.92%
+$2.69M 
ALLO Allogene Therapeutics Inc.
+3.54%
+$1.57M 
MNKD MannKind Corporation
+3.22%
+$792,000 
DSGN Design Therapeutics, Inc.
+3.06%
+$796,335.76 
ERAS Erasca, Inc.
+2.91%
+$12.99M 
MBX MBX Biosciences, Inc.
+2.22%
+$9.91M 
IBIO iBio, Inc.
+2.14%
+$58,604.01 
SVRA Savara Inc.
+2.09%
+$1.07M 
MIRM Mirum Pharmaceuticals Inc.
+1.89%
+$14.36M 
XLO Xilio Therapeutics, Inc.
+1.78%
+$67,600.8 
TRVI Trevi Therapeutics Inc.
+1.71%
+$3.08M 
EOLS Evolus Inc.
+1.68%
+$355,139.78 
ARQT Arcutis Biotherapeutics Inc.
+1.39%
+$3.55M 
STTK Shattuck Labs Inc.
+1.37%
+$375,000 
KRYS Krystal Biotech Inc.
+1.2%
+$1.89M 
NAMS NewAmsterdam Pharma Co. N.V.
+1.16%
+$5.61M 
CYTK Cytokinetics, Incorporated
+0.93%
+$788,717.72 
ASND Ascendis Pharma A/S
+0.92%
+$511,101.85 
AURA Aura Biosciences Inc.
+0.52%
+$284,000 
TARS Tarsus Pharmaceuticals Inc.
+0.47%
+$233,166.08 
IMCR Immunocore Holdings plc American Depositary Receipt
+0.03%
+$4,847.82 
NAMSW NewAmsterdam Pharma Company N.V.
0%
$0 
AUTL Autolus Therapeutics plc American Depositary Receipt
-3.15%
-$311,353.7 
LXEO Lexeo Therapeutics Inc.
-2.42%
-$578,967 
GLUE Monte Rosa Therapeutics, Inc.
-2.15%
-$340,000 
MAZE Maze Therapeutics Inc.
-1.75%
-$2.44M 
BBIO BridgeBio Pharma, Inc.
-1.66%
-$2.09M 
IRON Disc Medicine Inc.
-1.46%
-$1.59M 
ACRS Aclaris Therapeutics, Inc.
-1.36%
-$394,029.92 
VOR Vor Biopharma Inc.
-1.12%
-$661,421.6 
DYN Dyne Therapeutics Inc.
-1%
-$819,801.32 
ALKS Alkermes plc
-0.79%
-$273,251.63 
BCRX BioCryst Pharmaceuticals Inc.
-0.71%
-$280,646.8 
ZLAB Zai Lab Ltd.
-0.5%
-$247,303.5 
ACAD Acadia Pharmaceuticals Inc.
-0.46%
-$186,965.74 
RLAY Relay Therapeutics Inc.
-0.35%
-$71,098.51 
PVLA Pavella Therapeutics Inc.
-0.27%
-$370,608 
KLRA Kailera Therapeutics, Inc.
-0.17%
-$33,000 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 421 | Longs Won 254/421 60% | Profit Factor 7.28 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $27.48M |
| Average Win $13.08M | Best Trade (Aug 15) $280.43M | Sharpe Ratio -8.9 |
| Average Loss -$2.73M | Worst Trade (Aug 15) -$23.48M | Z-Score 3.47 (99.95%) |
| Commissions $0 | Avg. Trade Length 1y 6m | Expectancy $6.81M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% |
| Consecutive Losing Trades | 1,626 | 1,463 | 1,301 | 1,138 | 976 | 813 | 650 | 488 | 325 | 163 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals Inc. | 1.44M | $34.49M | $40.63M | - | $6.14M | 17.8% | -0.458% |
| ACHV Achieve Life Sciences Inc. | 7.61M | $49.72M | $57.8M | - | $8.07M | 16.23% | +4.69% |
| ACRS Aclaris Therapeutics, Inc. | 4.93M | $18.47M | $28.47M | - | $10M | 54.13% | -1.365% |
| ALKS Alkermes plc | 700,647 | $19.88M | $34.37M | - | $14.5M | 72.92% | -0.789% |
| ALLO Allogene Therapeutics Inc. | 22.45M | $50.51M | $46.02M | - | -$4.5M | -8.9% | +3.535% |
| ARQT Arcutis Biotherapeutics Inc. | 9.87M | $182.96M | $258.61M | - | $75.65M | 41.35% | +1.394% |
| ASND Ascendis Pharma A/S | 225,155 | $44.4M | $55.95M | - | $11.55M | 26.02% | +0.922% |
| AURA Aura Biosciences Inc. | 7.1M | $46.35M | $54.6M | - | $8.25M | 17.81% | +0.523% |
| AUTL Autolus Therapeutics plc American Depositary Receipt | 4.45M | $20.48M | $9.56M | - | -$10.92M | -53.32% | -3.153% |
| BBIO BridgeBio Pharma, Inc. | 1.55M | $44.81M | $123.63M | - | $78.82M | 175.88% | -1.662% |
| BCRX BioCryst Pharmaceuticals Inc. | 4.01M | $38.17M | $39.05M | - | $882,032.8 | 2.31% | -0.714% |
| CYTK Cytokinetics, Incorporated | 1.16M | $54.43M | $85.98M | - | $31.55M | 57.96% | +0.926% |
| DSGN Design Therapeutics, Inc. | 1.81M | $25.77M | $26.84M | - | $1.07M | 4.14% | +3.058% |
| DYN Dyne Therapeutics Inc. | 3.15M | $39.54M | $81.03M | - | $41.5M | 104.97% | -1.002% |
| EOLS Evolus Inc. | 2.63M | $23.63M | $21.45M | - | -$2.18M | -9.21% | +1.683% |
| ERAS Erasca, Inc. | 24.98M | $87.17M | $459.04M | - | $371.87M | 426.59% | +2.912% |
| GLUE Monte Rosa Therapeutics, Inc. | 1M | $16.45M | $15.5M | - | -$950,000 | -5.78% | -2.146% |
| IBIO iBio, Inc. | 1.95M | $3.77M | $2.79M | - | -$976,733.5 | -25.91% | +2.143% |
| IMCR Immunocore Holdings plc American Depositary Receipt | 484,782 | $15.03M | $16.58M | - | $1.55M | 10.32% | +0.029% |
| IRON Disc Medicine Inc. | 1.35M | $64.4M | $106.82M | - | $42.42M | 65.88% | -1.462% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Steve R. Bailey?
The largest contributions to the portfolio's profits come from the following stocks: BridgeBio Pharma, Inc - $130.07M, Alpine Immune Sciences Inc - $94.01M, Chinook Therapeutics, Inc - $91.87M, Rhythm Pharmaceuticals Inc - $71.74M, and Revolution Medicines Inc - $71.02M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: AnaptysBio Inc - $26.18M, Rocket Pharmaceuticals Inc - $22.03M, AN2 Therapeutics, Inc - $19.35M, IVERIC bio Inc - $17.46M, and Bicycle Therapeutics plc American Depositary Receipt - $16.36M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are Steve R. Bailey's monthly returns?
Steve R. Bailey's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Steve R. Bailey's strategy be considered aggressive or moderate?
Steve R. Bailey's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Steve R. Bailey's strategy?
Steve R. Bailey's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
